IP Library Granted Patent US 9,102,618
Granted Patent B2
US 9,102,618 · App. 14/172,391 · Granted Aug 11, 2015

Prodrugs of NH-acidic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,618
App. No.
14/172,391
Granted
Aug 11, 2015
Kind
B2
Abstract

The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

Claims (182)

1. A compound of having the formula:

wherein

represents a single or double bond;

R 1 is selected from —C(R A )(R B )—OC(O)OR 20 , —C(R A )(R B )—OC(O)R 20 , —C(R A )(R B )—OC(O)NR 20 R 21 ;

Each R A and R B independently selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;

Each R 20 and R 21 is independently selected from hydrogen, aliphatic, substituted aliphatic, aryl or substituted aryl;

Each R 3 , R 4 and R 5 is independently selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 , —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl;

each R 10 and R 11 is independently absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; alternatively two R 10 and R 11 together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;

A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, —S—, —O—, —S(O)—, —S(O) 2 —, —S[C(R 30 )(R 31 )] u —, —S(O)[C(R 30 )(R 31 )] u —, —S(O) 2 [C(R 30 )(R 31 )] u —, —O[C(R 30 )(R 31 )] u —, —N(R 30 )—, —N(R 30 )[C(R 31 )(R 32 )] u —, or —[C(R 30 )(R 31 )] u , or —C(O)[C(R 30 )(R 31 )] u —;

Each u is independently 1, 2, 3, 4, 5, 6 or 7;

D is selected from absent, —O—, —NR 33 , —C(R 34 )(R 35 )—, —S—, —S(O)—,—S(O) 2 —, or —C(O)—;

Each R 30 , R 31 , R 32 , R 33 , R 34 , and R 35 is independently selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl;

R 2 is selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl;

r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11;

each G 3 and G 4 is independently selected from —N—, —C(R 10 )—[C(R 10 )(R 11 )] a —, wherein

a is 0, 1 or 2;

m and q are independently selected from 0, 1, and 2;

X 20 is —C(R 10 )— or —N—; and,

p is selected 0, 1, 2 or 3.

2. A compound of claim 1 having the formula:

wherein

represents a single or double bond;

R 1 is selected from —C(R A )(R B )—OC(O)OR 20 , —C(R A )(R B )—OC(O)R 20 , —C(R A )(R B )—OC(O)NR 20 R 21 ;

Each R A and R B is independently selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;

Each R 20 and R 21 is independently selected from hydrogen, aliphatic, substituted aliphatic, aryl or substituted aryl;

Each R 3 , R 4 and R 5 is independently selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 , —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl;

Each R 10 and R 11 is independently absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; alternatively two R 10 and R 11 together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;

A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl, —S—, —O—, —S(O)—, —S(O) 2 —, —S[C(R 30 )(R 31 )] u —, —S(O)[C(R 30 )(R 31 )] u —, —S(O) 2 [C(R 30 )(R 31 )] u —, —O[C(R 30 )(R 31 )] u —, —N(R 30 )—, —N(R 30 )[C(R 31 )(R 32 )] u —, or —[C(R 30 )(R 31 )] u , or —C(O)[C(R 30 )(R 31 )] u —,

Each u is independently 1, 2, 3, 4, 5, 6 or 7;

D is selected from absent, —O—, —NR 33 , —C(R 34 )(R 35 )—, —S—, —S(O)—, —S(O) 2 —, or —C(O)—;

Each R 30 , R 31 , R 32 R 33 , R 34 , and R 35 is independently selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; and,

R 2 , p, r, m and q are as defined in claim 1 .

3. A compound of Formula XIIC:

wherein represents a single or double bond;

R 1 is selected from —C(R A )(R B )—OC(O)OR 20 , —C(R A )(R B )—OC(O)R 20 , or —C(R A )(R B )—OC(O)NR 20 R 21 ;

wherein each R A and R B is independently selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;

each R 20 and R 21 is independently selected from hydrogen, aliphatic, substituted aliphatic, aryl or substituted aryl; and,

w is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

4. A compound of Table H or a pharmaceutically acceptable salt thereof:

TABLE H

No

Structure

1100.

1101.

1102.

1103.

1104.

1105.

1106.

1107.

1108.

1109.

1110.

1111.

1112.

1113.

1114.

1115.

1116.

1117.

1118.

1119.

1120.

1121.

1122.

1123.

1124.

1125.

1126.

1127.

1128.

1129.

1130.

1131.

1132.

1133.

1134.

1135.

1136.

1137.

1138.

1139.

1140.

1141.

1142.

1143.

1144.

1145.

1146.

1147.

1148.

1149.

1150.

1151.

1152.

1153.

1154.

1155.

1156.

1157.

1158.

1159.

1160.

1161.

1162.

1163.

1164.

1165.

1166.

1167.

5. A compound of Table I or a pharmaceutically acceptable salt thereof:

No

Structure

1200.

1201.

1202.

1203.

1204.

1205.

1206.

1207.

1208.

1209.

1210.

1211.

1212.

1213.

1214.

1215.

1216.

1217.

1218.

1219.

1220.

1221.

1222.

1223.

1224.

1225.

1226.

1227.

1228.

1229.

1230.

1231.

1232.

1233.

1234.

1235.

1236.

1237.

1238.

1239.

1240.

1241.

1242.

1243.

1244.

1245.

1246.

1247.

1248.

1249.

1250.

1251.

1252.

1253.

1254.

1255.

1256.

1257.

1258.

1259.

1260.

1261.

1262.

1263.

1264.

1265.

1266.

1267.

.

Assignments (3)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →